MedTrace Logo

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

NCT04129411 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-05-20

Study results available
· View outcomes & findings →

Summary

Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.

Conditions

  • Papillary Thyroid Cancer
  • Papillary Thyroid Microcarcinoma

Interventions

DEVICE

RFA

Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.

Sponsors & Collaborators

Principal Investigators

  • Marius Stan, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2024-05-07
Completion
2024-05-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129411 on ClinicalTrials.gov